<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255875</url>
  </required_header>
  <id_info>
    <org_study_id>C4071001</org_study_id>
    <nct_id>NCT04255875</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of PF-07209326 in Healthy Participants</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF PF-07209326 IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 first-in-human single ascending dose and multiple dose study will be a
      randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and
      pharmacokinetics of PF-07209326.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">March 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 113 (MD)</time_frame>
    <description>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with laboratory abnormalities</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 113 (MD)</time_frame>
    <description>Percentage of subjects with laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in vital signs</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 113 (MD)</time_frame>
    <description>blood pressure, pulse rate, temperature, respiration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 113 (MD)</time_frame>
    <description>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with injection site reactions</measure>
    <time_frame>Day 1 up to Day 8 post each dose</time_frame>
    <description>Percentage of subjects with injection site reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with infusion site reactions</measure>
    <time_frame>Day 1 up to Day 8 post each dose</time_frame>
    <description>Percentage of subjects with infusion site reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK /Cmax</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / DN Cmax</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Dose normalized Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / Tmax</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / AUClast</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / DN AUClast</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Dose normalized AUClast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / AUCinf</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Area under the serum concentration time profile from time zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / DN AUCinf</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Dose normalized AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / t½</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Terminal half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / CL (IV only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / CL/F (SC only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / Vss (IV only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Volume of distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / Vz/F (SC only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Apparent volume of distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / F (SC only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Apparent bioavailability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: Cmax</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Maximum plasma concentration after the first and last doses over the dosing interval tau (1 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: Tmax</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Time to maximum plasma concentration after the first and last doses over the dosing interval tau (1 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: AUCtau</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
    <description>Area under the curve over the dosing interval tau (1 week) after the first and last doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: Cmin</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
    <description>Minimum plasma concentration over the dosing interval tau (1 week) after the first and last doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: t½</measure>
    <time_frame>Day 15 up to Day 113</time_frame>
    <description>Terminal half life after the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: Rac, Cmax</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Accumulation ratio for Cmax after the first and last doses over the dosing interval tau (1 week)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: Rac, AUCtau</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
    <description>Accumulation ratio of AUCtau after the first and last doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD:ADA and/or NAb</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Frequency of anti-drug antibody (ADA) and/or neutralizing antibody (NAb) productions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD:ADA and/or NAb</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Frequency of anti-drug antibody (ADA) and/or neutralizing antibody (NAb) productions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-07209326</intervention_name>
    <description>Participants will receive SC or IV single ascending doses</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

        Exclusion Criteria:

          1. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, immunocompromised (or known disorder of the immune
             system), cardiovascular, hepatic, psychiatric, neurological, or allergic disease
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
             at the time of dosing).

          2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;
             positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core
             antibody (HBcAb), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.

          3. History of active or latent tuberculosis (TB) regardless of treatment or positive
             QuantiFeron TB test.

          4. Participants with any of the following acute or chronic infections or infection
             history:

               -  Any infection requiring treatment within 2 weeks prior to the screening visit.

               -  Any infection requiring hospitalization, parenteral antimicrobial therapy within
                  30 days of the first dose of investigational product.

               -  Any infection judged to be an opportunistic infection, within the past 6 months
                  of the first dose of the investigational product.

               -  Known active or history of frequent bacterial, viral, fungal, mycobacterial or
                  other infections as determined by the PI.

               -  Participants with a fever within the last 7 days prior to dosing.

          5. Participants with a history of allergic or anaphylactic reaction to therapeutic or
             diagnostic protein.

          6. Other acute or chronic medical or psychiatric condition including recent (within the
             past year) or active suicidal ideation or behavior or laboratory abnormality that may
             increase the risk associated with study participation or investigational product
             administration or may interfere with the interpretation of study results and, in the
             judgment of the investigator, would make the participant inappropriate for entry into
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4071001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>single ascending dose</keyword>
  <keyword>multiple dose</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Phase 1</keyword>
  <keyword>First in human</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

